Ankle InjuriesPhase 3NCT01945034
5% Topical Ibuprofen (IBU) for Ankle Sprain
A Phase 3 study testing Topical IBU twice daily and Topical IBU three times daily in people with Ankle Injuries, run by Pfizer at 19 sites in United States.
Trial summary
This study is being conducted to evaluate the effects of IBU 5% Topical Gel versus topical placebo for the relief of pain associated with a first or second degree ankle sprain. Both twice daily and three times daily regimens will be evaluated. Read more about this study
- Who is it for?
- Ages 12 years and older
- Conditions the study is for
- Ankle Injuries
- What is being tested?
- Topical IBU twice daily and Topical IBU three times daily
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 304 participants
- Where
- 19 sitesUnited States
- Study dates
- Nov 2013to Feb 2015
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- First or second degree ankle sprain within 48 hours of first dose of study medication
- Medically cleared to participate
Who cannot join
- Similar injury of same joint within last 6 months
- Requires bed rest, surgery, or over-the-counter or prescription analgesics
Trial locations and contacts
19 sites in 1 country.
19 sites in 1 country
United States19 sites
Orange County Research Institute
Anaheim, California, 92801
Elite Clinical Trials LLLP
Blackfoot, Idaho, 83221
Danville Orthopedic Clinic
Danville, Virginia, 24541
Lillestol Research, LLC
Fargo, North Dakota, 58103
Clinical Trial Network
Houston, Texas, 77074
MedPharmics, LLC
Metairie, Louisiana, 70006
Sunrise Research Institute, Inc.
Miami, Florida, 33130
L&L Research Choices
Miami, Florida, 33144
Quality Clinical Research, Inc.
Omaha, Nebraska, 68114
Heartland Clinical Research, Inc.
Omaha, Nebraska, 68134
PMG Research of Salisbury
Salisbury, North Carolina, 28144
Clinical Trials of Texas, Inc.
San Antonio, Texas, 78229
Clinical Trials of Texas
San Antonio, Texas, 78229
Sports Medicine Associates of San Antonio
San Antonio, Texas, 78240
eStudy Site
San Diego, California, 92120
San Diego Sports Medicine and Family Health Center
San Diego, California, 92120
Helen Keller Hospital
Sheffield, Alabama, 35660
Doctors Research Network
South Miami, Florida, 33143
Visions Clinical Research - Tucson
Tucson, Arizona, 85712
About this study
Official title: Placebo-controlled, Double-blind Evaluation Of The Efficacy And Safety Of Ibuprofen 5% Topical Gel For The Treatment Of Ankle Sprain
This study is being conducted to evaluate the effects of IBU 5% Topical Gel versus topical placebo for the relief of pain associated with a first or second degree ankle sprain. Both twice daily and three times daily regimens will be evaluated.
- Conditions
- Ankle Injuries
- Being tested
- Topical IBU twice daily, Placebo twice daily, Topical IBU three times daily, Placebo three times daily
- Keywords
- topical ibuprofen, ankle sprain
- Medical subject headings
- Ankle Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Topical IBU twice dailyDrug
Topical gel administered as 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
Placebo twice dailyDrug
Topical gel administered as a 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
Topical IBU three times dailyDrug
Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
Placebo three times dailyDrug
Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
| Study group | Role | What they receive |
|---|---|---|
| Topical IBU twice daily | Experimental | Not described Receives: Drug: Topical IBU twice daily |
| Placebo twice daily | Placebo comparator | Not described Receives: Drug: Placebo twice daily |
| Topical IBU three times daily | Experimental | Not described Receives: Drug: Topical IBU three times daily |
| Placebo three times daily | Placebo comparator | Not described Receives: Drug: Placebo three times daily |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sum of Pain Intensity Difference (SPID) on Weight Bearing Over 3 Days (SPID WB0-3)
PI was assessed on an 11-point numerical rating scale from 0=no pain to 10=most severe pain. Pain intensity difference (PID) was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID was calculated as the time-weighted sum of PID scores over 3 days (72 hours). Total score ranges from -360 (higher pain relief) to 432 (lower pain relief) for SPID WB0-3. SPID is a value of change from baseline and as pain score at base line is usually higher than that at post baseline, a negative value of SPID indicates higher pain relief from baseline.
Measured: Over 3 Days (0-72 hours)
Sum of Ankle Pain Intensity Difference on Weight Bearing Over 24 Hours After Dose 1 (SPID WB24)
PI was assessed on an 11-point numerical rating scale from 0=no pain to 10=most severe pain. PID was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID was calculated as the time-weighted sum of PID scores over 24 hours. Total score ranges from -120 (higher pain relief) to 144 (lower pain relief) for SPID WB24. SPID is a value of change from baseline. Pain score at base line is usually higher than that at post baseline. So negative value of SPID indicates pain relief from baseline, while a positive value means a worst pain comparing to baseline, a negative value of SPID indicates higher pain relief from baseline.
Measured: 0 to 24 hours
Secondary outcomes (13)
Sum of Pain Intensity Difference at Rest Over 24 Hours on Day 1 (SPID R24)
PI was assessed on an 11-point numerical rating scale from 0=no pain to 10=most severe pain. PID was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID was calculated as the time-weighted sum of PID scores over 24 hours. Total score ranges from -240 (higher pain relief) to 96 (lower pain relief) for SPID at rest. SPID is a value of change from baseline. Pain score at base line is usually higher than that at post baseline. So negative value of SPID indicates pain relief from baseline, while positive value means a worst pain comparing to baseline, a negative value of SPID indicates higher pain relief from baseline.
Measured: 0 to 24 hours
Change From Baseline in Participant's Global Assessment of Ankle Injury at Day 3 and 10
Participant's global assessments of ankle injury was measured using 5-point scale: 1= Very Good (No symptoms and no limitations of normal activities), 2= Good (Mild symptoms and no limitation of normal activities), 3= Fair (Moderate symptoms and limitations of some normal activities), 4= Poor (Severe symptoms and inability to carry out most normal activities), 5= Very Poor (Very severe symptoms which are intolerable and inability to carry out all normal activities).
Measured: Baseline, Day 3, 10
Change From Baseline in Physician Global Assessment of Ankle Injury at Day 3 and 10
The physician assessment of the severity of the ankle injury was based on the participant's individual signs and symptoms which included pain, swelling, tenderness and limitation of range of movement, and was measured using 6-point scale: 0= Normal (No signs or symptoms) , 1= Very mild (Very mild signs and symptoms), 2= Mild (Mild signs and symptoms), 3= Moderate (Moderate signs and symptoms), 4= Severe (Severe signs and symptoms), 5= Very severe (Very severe signs and symptoms). A higher score is indicative of lesser improvement. Change from baseline was calculated as baseline value minus post-treatment value.
Measured: Baseline, Day 3, 10
Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points
PI in ankle pain at rest and upon weight bearing was assessed on an 11-point numerical rating scale from 0=no pain to 10=most severe pain. PID was the difference between baseline PI (prior to the first dose) and current PI at assessment. Pain score at baseline is usually higher than that at post baseline. So negative value of SPID indicates pain relief from baseline, while positive value means a worst pain comparing to baseline.
Measured: Baseline, 1, 2, 3, 4, 5, 6, 12(Day1),24(Day2),30(Day2),36(Day2),48(Day3),50(Day3),54(Day3),60(Day3),72(Day4),78(Day4),84(Day4), 96(Day5),102(Day5), 108 (Day5), 120(Day6),126(Day6),132(Day6),144(Day7),150(Day7),156(Day7) hours post first dose on Day 1
Sum of Pain Intensity Difference at Rest and on Weight Bearing Over 6 Hours on Day 1 and Over 2 Hours on Day 3
PI at rest and on weight bearing was assessed on an 11-point numerical rating scale from 0=no pain to 10=most severe pain. PID was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID 0-6 was calculated as the time-weighted sum of PID scores over 6 hours on Day 1, with a total score ranges from -30 (higher pain relief) to 36 (lower pain relief). SPID 0-12 was calculated as the time weighted sum of PID scores over 2 hours on Day 3, with a total score ranges from -10 (higher pain relief) to 12 (lower pain relief). SPID is a value of change from baseline. Pain score at base line is usually higher than that at post baseline. So negative value of SPID indicates pain relief from baseline, while positive value means a worst pain comparing to baseline, a negative value of SPID indicates higher pain relief from baseline.
Measured: Over 6 hours on Day 1, over 2 hours on Day 3
Sum of Pain Intensity Difference Scores at Rest Over 3 Days
PI was assessed on an 11-point numerical rating scale from 0=no pain to 10=most severe pain. PID was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID was calculated as the time-weighted sum of PID scores over 3 days (72 hours). Total score ranges from -360 (higher pain relief) to 432 (lower pain relief). SPID is a value of change from baseline. Pain score at base line is usually higher than that at post baseline. So negative value of SPID indicates pain relief from baseline, while positive value means a worst pain comparing to baseline, a negative value of SPID indicates higher pain relief from baseline.
Measured: Over 3 Days (0-72 hours)
Sum of Pain Intensity Difference Scores at Rest and on Weight Bearing Over 7 Days
PI was assessed on an 11-point numerical rating scale from 0=no pain to 10=most severe pain. PID was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID was calculated as the time-weighted sum of PID scores over 7 days (168 hours). Total score ranges from -840 (higher pain relief) to 1008 (lower pain relief). SPID is a value of change from baseline. Pain score at baseline is usually higher than that at post baseline. So negative value of SPID indicates pain relief from baseline, while positive value means a worst pain comparing to baseline, a negative value of SPID indicates higher pain relief from baseline.
Measured: Over 7 days (0-168 hours)
Change From Baseline in Participant Assessment of Normal Function and Activity at Day 3 and 10
Participant assessment of normal function was measured using a 5-point scale: 1= Normal walking/activity and no pain; 2= Normal walking/activity with pain; 3= Mildly restricted walking due to pain and can't resume normal activities; 4= Moderately restricted walking due to pain and can't resume normal activities; 5= Severely restricted walking due to pain and can't resume normal activities. The normal functioning and activity scores for each question range from 1 to 5, with higher scores indicating worsening of normal activity.
Measured: Baseline, Day 3, 10
Participant's Global Assessment of Medication at End of Study
Participants Global Assessment of Medication was used to rate the medication as a pain reliever. The responses of participants were recorded using 5-point scale: 1= Very Poor, 2= Poor, 3= Fair, 4= Good, 5= Very Good. The global assessment of medication scores for each question range from 0 to 5, giving a possible score range of 0 - 5, with higher scores indicating medication as a better pain reliever.
Measured: Day 10
Time to First Perceptible Relief and Meaningful Relief
Participants evaluated time to first perceptible relief by stopping a stopwatch labelled 'first perceptible relief' at moment participant first began to experience any relief, exact question asked was: "Stop stopwatch when you first begin to feel any pain-relieving effect whatsoever of product; that is, when you first feel a little relief". First perceptible relief was considered confirmed by meaningful relief if participant achieved both "first perceptible" and "meaningful" relief by either pressing second stopwatch or by indicating that his/her "first perceptible" relief was also "meaningful". For "time to meaningful relief," exact question asked was: "Stop this stopwatch when you have meaningful relief; that is, when relief from pain is meaningful to you." Stopwatches were active up to 3 hours after dosing or until stopped by participant, or rescue medication was administered.
Measured: 0 to 3 hours on Day 1
Time to Rescue Medication After Initial Dose, and After Each Subsequent Dose
Participants used only acetaminophen at a dose of 500 milligram (mg) every 6 hours product as needed (PRN) as rescue medication during the course of the study. Participants who used acetaminophen were to record its use, and date and time of administration in the participant diary. Time to rescue medication after initial dose, after each subsequent dose, provided that in each dose interval at least 25% of the participants take rescue medication was analyzed using the proportional hazard model with site, treatment group, and baseline categorical ankle pain terms in the model.
Measured: Post-Dose on Day 1 up to Day 10
Number of Doses of Rescue Medication Used During the First 7 Days of Dosing
Participants received only acetaminophen 500 mg every 6 hours PRN as rescue medication during the course of the study.
Measured: Baseline up to Day 7
Percentage of Participants Taking Rescue Medication
Participants used only acetaminophen at a dose of 500 mg every 6 hours PRN as analgesia or rescue therapy during the course of the study. Participants who used acetaminophen were to record its use, and date and time of administration in the participant diary.
Measured: Post first dose Day 1 up to Day 10
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2013 (estimated)
- Study startNov 2013
- Primary completionFeb 2015
- Study completionFeb 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Ankle InjuriesStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 304 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01945034
- Sponsor's protocol ID
- B3491009
- Status last verified
- Apr 2016
- First submitted
- 21 Jun 2013
- Last updated
- 26 May 2016
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 May 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Placebo-controlled, Double-blind Evaluation Of The Efficacy And Safety Of Ibuprofen 5% Topical Gel For The Treatment Of Ankle Sprain
- ClinicalTrials.gov ID
- NCT01945034
- Acronym / sponsor ID
- B3491009
- Conditions
- Ankle Injuries
- Keywords
- topical ibuprofen, ankle sprain
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 304 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- Nov 2013
- Primary completion
- Feb 2015 (actual)
- Study completion
- Feb 2015 (actual)
- First posted
- 18 Sep 2013 (estimated)
- Results
- Posted 26 May 2016
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is being conducted to evaluate the effects of IBU 5% Topical Gel versus topical placebo for the relief of pain associated with a first or second degree ankle sprain. Both twice daily and three times daily regimens will be evaluated.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Topical IBU twice daily | Experimental | Drug: Topical IBU twice daily |
| Placebo twice daily | Placebo comparator | Drug: Placebo twice daily |
| Topical IBU three times daily | Experimental | Drug: Topical IBU three times daily |
| Placebo three times daily | Placebo comparator | Drug: Placebo three times daily |
Who may qualify
- Ages
- 12 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (2 listed)
- First or second degree ankle sprain within 48 hours of first dose of study medication
- Medically cleared to participate
Key exclusion criteria (2 listed)
- Similar injury of same joint within last 6 months
- Requires bed rest, surgery, or over-the-counter or prescription analgesics
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Topical IBU twice dailyTopical gel administered as 4 inch strip twice daily for 7 days, and as needed for an additional 3 days | Drug | Topical IBU twice daily |
| Placebo twice dailyTopical gel administered as a 4 inch strip twice daily for 7 days, and as needed for an additional 3 days | Drug | Placebo twice daily |
| Topical IBU three times dailyTopical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days | Drug | Topical IBU three times daily |
| Placebo three times dailyTopical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days | Drug | Placebo three times daily |
Primary outcome
Sum of Pain Intensity Difference (SPID) on Weight Bearing Over 3 Days (SPID WB0-3)
Time frame: Over 3 Days (0-72 hours)
PI was assessed on an 11-point numerical rating scale from 0=no pain to 10=most severe pain. Pain intensity difference (PID) was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID was calculated as the time-weighted sum of PID scores over 3 days (72 hours). Total score ranges from -360 (higher pain relief) to 432 (lower pain relief) for SPID WB0-3. SPID is a value of change from baseline and as pain score at base line is usually higher than that at post baseline, a negative value of SPID indicates higher pain relief from baseline.
Sum of Ankle Pain Intensity Difference on Weight Bearing Over 24 Hours After Dose 1 (SPID WB24)
Time frame: 0 to 24 hours
PI was assessed on an 11-point numerical rating scale from 0=no pain to 10=most severe pain. PID was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID was calculated as the time-weighted sum of PID scores over 24 hours. Total score ranges from -120 (higher pain relief) to 144 (lower pain relief) for SPID WB24. SPID is a value of change from baseline. Pain score at base line is usually higher than that at post baseline. So negative value of SPID indicates pain relief from baseline, while a positive value means a worst pain comparing to baseline, a negative value of SPID indicates higher pain relief from baseline.
13 secondary outcomes
Sum of Pain Intensity Difference at Rest Over 24 Hours on Day 1 (SPID R24)
Time frame: 0 to 24 hours
Change From Baseline in Participant's Global Assessment of Ankle Injury at Day 3 and 10
Time frame: Baseline, Day 3, 10
Change From Baseline in Physician Global Assessment of Ankle Injury at Day 3 and 10
Time frame: Baseline, Day 3, 10
Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points
Time frame: Baseline, 1, 2, 3, 4, 5, 6, 12(Day1),24(Day2),30(Day2),36(Day2),48(Day3),50(Day3),54(Day3),60(Day3),72(Day4),78(Day4),84(Day4), 96(Day5),102(Day5), 108 (Day5), 120(Day6),126(Day6),132(Day6),144(Day7),150(Day7),156(Day7) hours post first dose on Day 1
Sum of Pain Intensity Difference at Rest and on Weight Bearing Over 6 Hours on Day 1 and Over 2 Hours on Day 3
Time frame: Over 6 hours on Day 1, over 2 hours on Day 3
Sum of Pain Intensity Difference Scores at Rest Over 3 Days
Time frame: Over 3 Days (0-72 hours)
Sum of Pain Intensity Difference Scores at Rest and on Weight Bearing Over 7 Days
Time frame: Over 7 days (0-168 hours)
Change From Baseline in Participant Assessment of Normal Function and Activity at Day 3 and 10
Time frame: Baseline, Day 3, 10
Participant's Global Assessment of Medication at End of Study
Time frame: Day 10
Time to First Perceptible Relief and Meaningful Relief
Time frame: 0 to 3 hours on Day 1
Time to Rescue Medication After Initial Dose, and After Each Subsequent Dose
Time frame: Post-Dose on Day 1 up to Day 10
Number of Doses of Rescue Medication Used During the First 7 Days of Dosing
Time frame: Baseline up to Day 7
Percentage of Participants Taking Rescue Medication
Time frame: Post first dose Day 1 up to Day 10
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 May 2016.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Ankle Injuries
Recruiting
Investigating Auto Adjusting Dynamic AFO
Lower Limb; Fusion, Congenital, Lower Limb Fracture
Not yet recruiting
Functional Recovery After a Recent Lateral Ankle Sprain With Early Initiation of Rehabilitation: Changes in the Ankle-GO Score and Its Association With Return to Sport and Recurrent Sprains.
Ankle Sprain
Recruiting
Enovis High Ankle Sprain Brace Testing
Athletes in Cutting Sports
Recruiting
Lateral Ankle Treatment
Avulsion Fracture
RecruitingObservational study
Use of Bioresorbable Magnesium Set Screws in Syndesmotic Injuries: a Pilot Study
Syndesmotic Injury, Trimalleolar Fracture
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
19 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Topical IBU twice daily and Topical IBU three times daily in people with Ankle Injuries, run by Pfizer at 19 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 May 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 19 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 26 May 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sum of Pain Intensity Difference (SPID) on Weight Bearing Over 3 Days (SPID WB0-3) (time frame: Over 3 Days (0-72 hours)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 May 2016.